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Summary
Background In South Africa, sputum smear microscopy has been replaced with Xpert MTB/RIF as the initial 
diagnostic test for tuberculosis. In a pragmatic parallel cluster-randomised trial, we evaluated the eﬀ ect on patient and 
programme outcomes.
Methods We randomly allocated 20 laboratories (clusters) in medium-burden districts of South Africa to either an Xpert 
(immediate Xpert) or microscopy (Xpert deferred) group (1:1), stratiﬁ ed by province. At two primary care clinics per 
laboratory, a systematic sample of adults giving sputum for tuberculosis investigation was assessed for eligibility. The 
primary outcome was mortality at 6 months from enrolment. Masking of participants’ group allocation was not possible 
because of the pragmatic trial design. The trial is registered with the ISRCTN registry (ISRCTN68905568) and the 
South African Clinical Trial Register (DOH-27-1011-3849).
Findings Between June and November, 2012, 4972 people were screened, and 4656 (93·6%) enrolled (median age 
36 years; 2891 [62%] female; 2212 [62%] reported being HIV-positive). There was no diﬀ erence between the Xpert and 
microscopy groups with respect to mortality at 6 months (91/2324 [3·9%] vs 116/2332 [5·0%], respectively; adjusted 
risk ratio [aRR] 1·10, 95% CI 0·75–1·62]).
Interpretation Xpert did not reduce mortality at 6 months compared with sputum microscopy. Improving outcomes in 
drug-sensitive tuberculosis programmes might require not only better diagnostic tests but also better linkage to care.
Funding Bill & Melinda Gates Foundation.
Copyright © Churchyard et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Improved diagnosis of tuberculosis is a global priority for 
tuberculosis control. Xpert MTB/RIF (Cepheid, Sunnyvale, 
CA, USA) is a rapid, molecular, cartridge-based test that 
represents an important advance in tuber culosis diag-
nostics, with consistently better sensitivity than sputum 
smear microscopy, and an immediate rifampicin resistance 
result.1–3 The 2013 WHO guidelines include a conditional 
recommendation for Xpert MTB/RIF as the initial 
diagnostic test in all adults with suspected tuber culosis, 
acknowledging resource implications.4 The impact of 
Xpert MTB/RIF will, however, depend on the system in 
which it is used5,6 and countries will need evidence about 
patient, programme, and cost-eﬀ ectiveness outcomes to 
inform policy recommendations for programmatic imple-
men tation of the test in their settings.7
In 2011, South Africa, with the third largest number of 
tuberculosis cases globally, made a policy decision to 
replace sputum smear microscopy with Xpert MTB/RIF 
as the ﬁ rst-line test for tuberculosis across the entire 
national laboratory service.8 The South African Xpert 
MTB/RIF programme is the largest in the world, 
accounting for more than half of all cartridges procured 
globally in 2013.
Here, we use a pragmatic cluster-randomised trial 
embedded in the South African national roll-out of Xpert 
MTB/RIF to assess the eﬀ ect of Xpert MTB/RIF use 
versus sputum smear microscopy use on mortality, 
proportion test positive, proportion treated and the initial 
loss to follow-up in people being investigated for 
tuberculosis”
Methods
Study design
The XTEND study was a pragmatic, two-arm, parallel, 
cluster-randomised trial to assess the eﬀ ect of Xpert 
MTB/RIF implementation in South Africa. A cluster was 
deﬁ ned as a laboratory and two primary care clinics served 
by, but not co-located with, that laboratory. Further details 
of how clinics and laboratories were selected is in the 
appendix.
The XTEND protocol was approved by the ethics 
committees of the University of the Witwatersrand; the 
University of Cape Town; the London School of Hygiene 
& Tropical Medicine; and WHO. The study protocol is 
available online. The study is registered with the 
ISRCTN trials register (ISRCTN68905568) and the 
South African Clinical Trials Register (DOH-27-1011-
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3849). An independent Data Safety and Monitoring 
Board monitored the study every year.
Setting and participants
From March, 2011, Xpert MTB/RIF was rolled out in four 
phases: (1) a pilot phase in high-burden districts, followed 
by full implementation in laboratories in (2) high-burden, 
(3) medium-burden, and (4) low-burden districts. This 
trial was embedded in phase 3 of the national roll-out. 
Laboratories identiﬁ ed by the National Health Laboratory 
Service in July, 2011, as sites for a GeneXpert 16-module 
instrument (using data on the number of specimens 
submitted for sputum microscopy), were eligible for 
inclusion. Laboratories were ineligible if they were part of 
other Xpert MTB/RIF evaluations, already had a 
GeneXpert instrument, did not comply with standard of 
care tuberculosis diagnostics or were likely to be closed 
down for operational reasons during the study. In 
collaboration with the National Department of Health 
and the National Health Laboratory Service, we identiﬁ ed 
20 laboratories in medium-burden districts in four 
provinces. Laboratories were grouped into four strata, 
based on province, and randomised by a statistician using 
Stata (version 11, StataCorp LP, College Station, Texas) to 
either the Xpert (immediate implementation) or the 
microscopy (with Xpert implementation deferred) study 
group.
From the primary care clinics currently served by the 
included laboratories, we selected two clinics per 
laboratory after a review of the number of sputum 
specimens sent to the National Health Laboratory Service 
in 2009–10. Clinics were not eligible for selection if they 
sent sputum specimens to other laboratories that use 
Xpert MTB/RIF; were currently or planning to use Xpert 
MTB/RIF as a point-of-care test in the next 12 months; 
were located on the same site as the associated laboratory 
(because this does not reﬂ ect typical clinics in South 
Africa); or were conducting other research projects 
related to tuberculosis. Hospital sites were excluded 
because it was likely that testing was done on site, rather 
than at a separate laboratory.
Participants were eligible for inclusion if they were aged 
18 years or older, not on tuberculosis treatment, had had a 
sputum specimen requested by clinic staﬀ  to investigate 
for possible tuberculosis, resident in the clinic catchment 
area, and not planning to relocate within the next 
8 months. All participants gave informed written and 
witnessed verbal consent. Study staﬀ  recruited participants 
from a systematic sample of clinic attendees who satisﬁ ed 
inclusion criteria. Identical methods for recruitment and 
similar calendar recruit ment periods were used in each 
study group. At clinics investigating fewer than ﬁ ve 
patients per day for tuberculosis, sequential patients 
referred to study staﬀ  were screened for enrolment. At 
clinics investigating 6–10 and 11–15 persons with 
suspected tuberculosis per day, every second or third 
person was screened for enrol ment, respectively. At 
enrolment, personal identiﬁ ers, such as South African 
identity number, locator infor mation (including 
participant-nominated contacts), demo graphic and 
clinical data relevant to tuberculosis and mortality risk, 
were collected including presence of tuberculosis 
symptoms, such as cough, weight loss, night sweats, and 
fever. Tracking details (name, date, barcode) of the sputum 
specimen requested by clinic staﬀ  at enrolment were 
recorded.
Research in context
Evidence before this study
The aim of the XTEND study was to assess the eﬀ ects of 
replacing smear microscopy with Xpert MTB/RIF on outcomes 
in people being investigated for tuberculosis, in the context 
of South African national roll-out of thi s test. South Africa 
was the ﬁ rst country to replace smear microscopy with Xpert 
MTB/RIF nationwide, and thus no similar data were available 
at the time we were planning the trial. We, therefore, did not 
do a systematic review as part of planning the trial. 
Subsequently, we searched PubMed for studies published 
from Jan 1, 2010, to Oct 31, 2014 using the terms tuberculosis 
AND randomised controlled trial AND (Xpert* OR Genexpert 
OR MTB/RIF), which identiﬁ ed only the TB-NEAT trial. This 
trial compared Xpert MTB/RIF with smear microscopy, with 
same-day results for both testing procedures; all participants 
also underwent same-day chest radiography. The primary 
outcome was morbidity, measured by TBscore, which was not 
diﬀ erent between study groups. The proportion of 
participants starting treatment for tuberculosis was high 
(more than 40% by day 56), and in many patients the 
decision to treat was based on radiological evidence, and did 
not diﬀ er by study group. There was no diﬀ erence in mortality 
(8% by day 56 in both groups).
Added value of this study
The XTEND trial provides robust evidence that Xpert MTB/RIF 
did not aﬀ ect patient-relevant outcomes in the context of 
routine implementation in South Africa.
Implications of all the available evidence
Xpert MTB/RIF did result in a 50% increase in the number of 
people with bacteriological conﬁ rmation of tuberculosis, 
meaning that nurses could start treatment immediately for more 
people. 16% of people with a positive tuberculosis test result (by 
either method) did not start treatment at the clinic where the 
test was taken: tuberculosis programmes need to close this gap. 
The risk of death by 6 months’ was higher in people who did not 
know their HIV status, or who were HIV-positive but were not 
taking antiretroviral therapy. People being tested for tuberculosis 
should know their HIV status, and health systems need to 
facilitate prompt linkage to HIV care for those who test positive.
For the study protocol see 
http://www.auruminstitute.org/
index.php?option=com_phocad
ownload&view=category&id=8&I
temid=417
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Procedures
GeneXpert 16-module instruments were introduced into 
laboratories assigned to the Xpert group (equivalent to the 
“intervention”). Laboratories assigned to the microscopy 
group continued to use quality-assured smear microscopy 
during enrolment of study participants (equivalent to the 
control condition), but implemented Xpert MTB/RIF 
about 6 months after enrolment was completed. All 
laboratory staﬀ  received training from the National Health 
Laboratory Service on specimen processing, instrument 
operation and maintenance, and documentation of results. 
Clinic staﬀ  were trained by the National Department of 
Health on the South African algorithm for Xpert MTB/RIF 
use (appendix). Additional information on Xpert MTB/RIF 
implementation is provided in the appendix.
All patient management, including investigations for 
tuberculosis, selection of tuberculosis treatment regimens, 
directly observed therapy, adherence monitoring, and 
antiretroviral therapy, was by health service staﬀ  in line 
with routine practice, and the study was designed in a way 
that would not aﬀ ect practice in either group. In the Xpert 
group, people with suspected tuberculosis had one spot-
sputum specimen collected for Xpert MTB/RIF testing at 
the associated laboratory. In the microscopy group, people 
requiring investigation for tuberculosis had two sputum 
specimens collected for ﬂ uorescence microscopy. Sub-
sequent clinical management of people who were index-
test negative was at the discretion of clinic staﬀ , guided by 
the relevant diagnostic algorithm, which, for HIV-positive 
people, included chest radiography, trial of antibiotics, and 
collection of sputum for mycobacterial culture (appendix). 
In both study groups, sputum specimens were transported 
to the laboratories at least once per day and the target 
turnaround time for results was 48 h.
Consistent with the parallel design, participants were 
enrolled over a similar calendar period across all clusters. 
In the Xpert group, recruitment started a median of 
3·6 months (range 1·0–7·4) after Xpert MTB/RIF was 
implemented, so that clinic staﬀ  had an opportunity to 
become familiar with the new procedures before 
enrolment started. In the microscopy group, enrolment 
began at the earliest opportunity.
In the microscopy group, two specimens were 
requested, versus one in the Xpert arm; thus any 
specimen collected within 4 days of enrolment was 
regarded as an index specimen, in both study groups. 
Study staﬀ , who were unaware of the index test result, 
telephoned participants 1 week and 1, 2, and 4 months 
after enrolment to maintain contact and update locator 
information. Participants who were successfully contacted 
by telephone were sent a mobile phone airtime voucher 
of small value (less than US$2) as an incentive to remain 
contactable during the study. If participants were not 
contactable after 3 attempts, we contacted the participant’s 
nominated contact or made a home visit to re-establish 
contact. Before the 6-month interview, study staﬀ 
reviewed patients’ clinic records for information such as 
results of index and subsequent tests and tuberculosis 
treatment and/or antiretroviral therapy start dates. If a 
participant had attended another clinic or a hospital 
during this time, as reported through the interview with 
the participant or a nominated contact (if the participant 
had died), or from information obtained from a record 
review at the enrolment clinic, study staﬀ  attempted to 
source patient data from these clinics and hospitals.
At 6 months from enrolment, study staﬀ  interviewed 
participants by telephone, or at a home visit, to ascertain 
whether the participant had started tuberculosis 
treatment or antiretroviral therapy and, if so, treatment 
start dates. Participants whose index test result was 
positive and who had not started tuberculosis treatment 
were referred for treatment.
All data (including participant identiﬁ ers, enrolment 
and follow-up questionnaires, visit contact records, and 
information from case notes) were collected using a 
custom-designed data collection application on a smart-
phone (appendix).
Primary health clinic staﬀ  identiﬁ ed people to be 
investigated for tuberculosis, collected sputum specimens, 
and labelled sputum jars and specimen request forms 
with a unique laboratory barcode, which was recorded in 
the tuberculosis register. Study staﬀ  obtained the 
laboratory barcodes of sputum specimens from the 
tuberculosis register on the day of enrolment. Immediately 
before the 6-month follow-up interview, study staﬀ 
accessed results of the index test, where available, so that 
if a participant had a positive index test result but had not 
started treatment, appropriate advice could be given. The 
National Health Laboratory Service Corporate Data 
Warehouse assisted with data matching and retrieval of 
sputum results from all participants. Where matching 
was unsuccessful, results were obtained directly from 
laboratories or from the tuberculosis register.
We recorded deaths through reports from participant-
nominated contacts, clinic staﬀ , and by accessing the 
Department of Home Aﬀ airs vital statistics database 
using participants’ South African identiﬁ cation numbers. 
An Endpoints Committee, unaware of group allocation, 
assigned vital status for a small number of participants 
where data were conﬂ icting. Participants starting 
tuberculosis treatment were identiﬁ ed by self-report at 
the 6-month follow-up interview and through record 
review at the index clinic or other facilities.
Study outcomes
The primary outcome was mortality, measured 6 months 
after enrolment. Secondary outcomes included (1) 
proportion with a positive index test result; (2) in 
participants with a positive result, initial loss to follow-up, 
deﬁ ned as the proportion not started on tuberculosis 
treatment within 28 days of enrolment; (3) proportion of 
the overall cohort starting tuberculosis treatment by 
6 months from enrolment. In a post-hoc analysis of data 
from participants who were treated for tuberculosis, we 
See Online for appendix
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compared the proportion with microbiologically 
conﬁ rmed tuberculosis, deﬁ ned as any positive Xpert 
MTB/RIF, microscopy or culture result, in each study 
group.
Statistical analysis
To inform the sample size calculation we reviewed the 
limited epidemiological and interventional research data 
that were available. In a study from KwaZulu-Natal of 
people being investigated for tuberculosis, HIV 
prevalence was 84% among those for whom HIV status 
was known. Data from the Western Cape and KwaZulu-
Natal in South Africa suggested a risk of death of 2–11% 
in people being investigated for tuberculosis at 2 months’ 
follow-up. We also used data (provided by Prof Mark Nicol, 
University of Cape Town) from a pilot study in two 
primary health clinics in the Western Cape. Preliminary 
results show that mortality at 2 months’ follow-up in a 
group randomly allocated testing with Xpert MTB/RIF 
was 74% lower than that in a group diagnosed with 
microscopy (0·8% vs 3·1%, respectively). On the basis of 
these data, we estimated that, in our study, Xpert 
MTB/RIF might be associated with a 50% reduction in 
mortality by 6 months from enrolment.
We assumed mortality of 5% in the microscopy group. 
Therefore, with 10 clusters per group, 220 people per 
cluster, and a coeﬃ  cient of variation of 0·25, we 
estimated that there would be approximately 90% power 
to detect a 50% reduction in mortality in the Xpert group.
We analysed data using methods appropriate to the 
trial design, with a small number of clusters (see 
appendix), as described in a predeﬁ ned analysis plan.9 
Brieﬂ y, we adopted a cluster-level analysis taking into 
account the stratiﬁ ed randomisation. We used log-
transformed cluster-level risk or rates to estimate 
geometric means for the two study groups. An 
approximate SE for the log (risk or rate ratio) based on 
geometric means of cluster risks or rates was calculated 
by two-way ANOVA on stratum, group, and the 
interaction between stratum and group.
As is not uncommon in cluster-randomised trials with a 
small number of clusters, we noted baseline imbalance 
between study groups in some factors associated with 
mortality, and we, therefore, adjusted for these individual-
level baseline factors using a two-stage approach.9 In 
stage 1, a regression model at the individual level, 
including terms for the adjustment factors and strata, but 
not study group, was ﬁ tted, and the expected number of 
outcomes accumulated at the cluster level. In stage 2, at 
the cluster level, linear regression of the log (observed/
expected outcomes) on stratum and group was used to 
estimate the risk/rate ratio. We calculated an approximate 
SE for the log (risk ratio) using similar approach as 
before. A post-hoc sensitivity analysis for the primary 
outcome was also done with logistic regression random-
eﬀ ects regression.
Role of the funding source
The funder played no role in the study design, 
implementation, data collection, analysis or decision to 
publish. The corresponding author conﬁ rms that he had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
From June to November, 2012, we screened 4972 adults, 
of whom 119 (2·4%) were ineligible, 141 (2·8%) declined 
enrolment, and 4712 were enrolled (ﬁ gure). Subsequently, 
56 participants were withdrawn, leaving 4656 participants 
(median age 36 years, 62% female; table 1) in the analysis 
for the primary outcome.
Around three quarters (3542 [76%]) of participants 
reported knowing and were willing to share their HIV 
Figure 1: Trial proﬁ le
21 laboratories (clusters) 
assessed for eligibility
20 laboratories randomised
1 laboratory excluded
10 laboratories randomly allocated 
to sputum microscopy 
2431 participants screened for eligibility
Median 242 participants per cluster 
(range 231–262)
45 in 9 clusters (range 2–8) 
were ineligible
18 in 4 clusters declined 
enrolment (range 1–11)
10 laboratories randomly allocated 
to Xpert MTB/RIF 
2541 participants screened for eligibility
Median 253 participants per cluster 
(range 233–299)
74 in 9 clusters (range 2–18) 
were ineligible
123 in 7 clusters declined 
enrolment (range 7–43)
2344 participants (from 10 clusters) 
were enrolled
Median 234·5 participants per cluster 
(range 223–242)
2368 participants (From 10 clusters) 
were enrolled
Median 236·5 participants per cluster 
(range 229–254)
20 participants withdrawn
12 were under age (in 6 clusters)
4 signed wrong consent form 
and refused to reconsent
1 did not submit a specimen
3 conﬁrmed to be on treatment 
at enrolment (in 3 clusters)
2324 from 10 clusters included in analysis
Median 232 participants per cluster 
(range 223–239)
2208 alive at 6 months
91 died within 6 months
25 lost to follow up at 6 months
36 participants withdrawn
9 were under age (in 6 clusters)
19 did not submit a specimen
1 missing crucial contact 
information (withdrawn 
by site)
7 conﬁrmed to be on treatment 
at enrolment (in 4 clusters)
2332 from 10 clusters included in analysis
Median 235 participants per cluster 
(range 227–239)
2193 alive at 6 months
116 died within 6 months
23 lost to follow up at 6 months
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status, of whom 2206 (62%) were HIV positive, with no 
diﬀ erence between study groups. Of those who reported 
being HIV positive, 33% (729/2206) had ever been on 
antiretroviral therapy and the median self-reported CD4 
cell count (n=1130) was 310 cells per μL (IQR 183–470). 
Baseline variables were similar by study group, except 
that participants in the Xpert group were less likely than 
those in the microscopy group to have a body-mass index 
<18·5 kg/m² and more likely to report no tuberculosis 
symptoms (table 1).
Vital status at 6 months from enrolment was known for 
4608 (99·0%) participants and 207 deaths occurred at a 
relatively constant rate during follow-up (data not 
shown). Based on the total cohort of 4656 participants, 
the 6-month mortality risk was 3·9% (91/2324) and 5·0% 
(116/2332) in the Xpert and microscopy groups, 
respectively, giving a risk ratio, adjusted for randomisation 
stratum only, of 0·86 (95% CI 0·56–1·28; p=0·43; table 2, 
appendix table 1). After adjusting for age group, sex, 
body-mass index (BMI) group, number of tuberculosis 
symptoms, self-reported HIV status, and randomisation 
stratum, the risk ratio was 1·10 (95% CI 0·75–1·62; 
p=0·61). Sensitivity analyses excluding those with 
unknown vital status at 6 months (n=48), or assuming 
those with unknown vital status were deaths, gave similar 
results. In a post-hoc sensitivity analysis using a logistic 
regression random-eﬀ ects model, we obtained an 
odds ratio, adjusted for randomisation stratum, of 
0·79 (95% CI 0·57–1·09; p=0·16) and a fully adjusted (for 
the same factors as previously mentioned) odds ratio of 
1·03 (95% CI 0·74–1·44; p=0·87).
In an analysis which was not prespeciﬁ ed but was done 
to help explain our results, individual-level risk factors 
associated with an increased risk of death included being 
simultaneously HIV-positive (self-reported) and 
antiretroviral therapy naïve (aOR 3·32, 95% CI 
2·03–5·41), or not knowing HIV status (2·41, 1·47–3·98), 
versus being HIV negative; lower BMI (<18·5 kg/m² vs 
18·5–24·9 kg/m²: aOR 1·40, 95% CI 0·94–2·07]), 
increasing age (<30 versus ≥50 years: aOR 2·53, 95% CI 
1·59–4·04) and increasing number of tuberculosis 
symptoms (of current cough, night sweats, fever, or 
weight loss (table 3). The coeﬃ  cient of variation for the 
primary outcome, taking into account the stratiﬁ ed 
design, was 0·24.
Results of the index test were known for 94·7% (n=4411) 
of participants. The proportion with a positive index test 
result was higher in the Xpert group than in the 
microscopy group and, after adjustment for baseline 
imbalance, there was a 49% greater proportion with a 
positive index test result in the Xpert group (table 2). In 
the Xpert group, 4·0% (8/200) of participants with a 
positive Xpert MTB/RIF test had a positive rifampicin-
resistance result.
By 6 months from enrolment, 541 (11·6%) participants 
investigated for tuberculosis had started tuberculosis 
treatment, with rates not varying between groups 
Xpert (n=2324) Microscopy 
(n=2332)
Age (years) 35 (28–45) 37 (29–48)
Female sex 1493 (64·2%) 1398 (59·9%)
Born in South Africa 2148 (92·4%) 2218 (95·1%)
Single marital status 1233 (53·1%) 1305 (56·0%)
Main income source
Employed 968 (41·6%) 1093 (46·9%)
Government grant 485 (20·9%) 363 (15·6%)
Other 871 (37·5%) 876 (37·6%)
Dwelling
House 1211 (52·1%) 1557 (66·8%)
Traditional 601 (25·9%) 378 (16·2%)
Other 512 (22·0%) 397 (17·0%)
HIV status, self-report
Negative 639 (27·5%) 697 (29·9%)
Positive* 1052 (45·3%) 1154 (49·5%)
Unknown 633 (27·2%) 481 (20·6%)
CD4 count (self-report [cells/μL])† 303 (171–457) 315 (192–480)
Ever taken ART (if known HIV 
positive)
352/1052
(33·5%)
377/1154
(32·7%)
Time on ART (years) 1·8 (0·7–3·7) 1·2 (0·4–3·0)
Has had previous tuberculosis 344 (14·8%) 374 (16·0%)
BMI (kg/m²)
<18·5 202 (8·7%) 288 (12·4%)
18·5–25·0 1062 (45·7%) 1077 (46·2%)
>25·0 1060 (45·6%) 967 (41·5%)
Karnofsky score
≤80 960 (41·3%) 981 (42·1%)
90 941 (40·5%) 1055 (45·2%)
100 423 (18·2%) 296 (12·7%)
Symptoms reported
Cough 1879 (80·9%) 1952 (83·7%)
Night sweats 946 (40·7%) 1152 (49·4%)
Weight loss 1030 (44·3%) 1210 (51·9%)
Fever 886 (38·1%) 1206 (51·7%)
Total number of symptoms‡
0 227 (9·8%) 139 (6·0%)
1 547 (23·5%) 456 (19·6%)
2 752 (32·4%) 628 (27·0%)
≥3 798 (34·3%) 1109 (47·5%)
Main reason for visit
TB symptoms 1689 (72·7%) 1735 (74·4%)
HIV care 194 (8·3%) 215 (9·2%)
HIV test 140 (6·0%) 150 (6·4%)
General/chronic 164 (7·1%) 158 (6·8%)
Antenatal clinic 126 (5·4%) 50 (2·1%)
Other 11 (0·5%) 24 (1·0%)
Data are n(%) or median (IQR) or n/N (%) unless otherwise stated. 
TB=tuberculosis. ART=antiretroviral therapy *Percentage HIV positive out of 
those with known HIV status 62·2% (1052/1691) and 62·3% (1154/1851) in the 
Xpert and microscopy arms, respectively. † In the Xpert group n=521, and in the 
microscopy group n=609. ‡Of current cough, night sweats, fever, or weight loss.
Table 1: Baseline characteristics of the enrolled population 
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(table 2). Of the 541 participants who had started 
treatment for tuberculosis, a greater proportion in the 
Xpert than the microscopy group had microbiological 
conﬁ rmation (table 2). The median time to starting 
tuberculosis treatment was 7 days in the Xpert group and 
10 days in the microscopy group.
Initial loss to follow-up was documented for 16·0% 
(60/374) of participants with a positive index test result, 
which was similar by study group (table 2).
Discussion
We had a rare opportunity to embed a randomised 
evaluation into South Africa’s national roll-out of Xpert 
MTB/RIF, allowing us to assess the eﬀ ectiveness of the 
test under programmatic conditions. In people tested for 
tuberculosis, most of whom were HIV-positive, we found 
that, compared with sputum microscopy, implementation 
of Xpert MTB/RIF did not reduce mortality at 6 months, 
the proportion of people who had started tuberculosis 
treatment at 6 months, nor the time to treatment for 
people with a positive test result, although it did result in 
a higher proportion of positive test results.
Mortality in our study population was high, and, 
contrary to previous assumptions,11, 12 not reduced after 
implementation of Xpert MTB/RIF. Our study was not 
designed to determine causes of death, but the strong 
association of death with unknown HIV status and, for 
HIV-positive participants, the protective eﬀ ect of 
antiretroviral therapy, suggest that HIV-related 
immunosuppression had an important role. That the 
deaths occurred at a relatively constant rate during the 
6 months of follow-up suggests opportunities for 
interventions to reduce mortality, and easily-determined 
markers (older age, multiple tuberculosis symptoms, as 
well as unknown HIV status and not taking antiretroviral 
therapy) could identify those at highest risk. In future 
analyses, we will explore adherence to the recommended 
post-test diagnostic algorithms, and individual and 
health system barriers to algorithm adherence. Our data 
support the policy that people being investigated for 
tuberculosis should know their HIV status, and linkage 
to HIV care should be facilitated for those who are HIV 
positive.
The 49% increase in the proportion with a positive 
index test result in the Xpert group is better than results 
from meta-analysis of laboratory-based evaluations of 
Xpert* Microscopy* Ratio measure (95% CI)
Unadjusted p Adjusted p
Mortality risk 0–6 months 91/2324 (3·9%) 116/2332 (5·0%) 0·86 (0·56–1·28) 0·43 1·10 (0·75–1·62) † 0·61
Tested positive for tuberculosis 200/2176 (9·2%) 174/2235 (7·8%) 1·27 (0·81–2·00) 0·27 1·49 (1·00–2·23)‡ 0·05
Initial loss to follow-up§ 34/200 (17·0%) 26/174 (14·9%) 0·97 (0·48–1·96) 0·93 0·96 (0·48–1·93)¶ 0·91
Treated for tuberculosis 250/2324 (10·8%) 291/2332 (12·5%) 0·88 (0·60–1·29) 0·48 1·04 (0·76–1·43)‡ 0·79
Tuberculosis microbiologically conﬁ rmed 196/250 (78·4%) 189/291 (65·0%) 1·21 (0·99–1·47) 0·06 1·20 (0·98–1·47) ‡ 0·07
Data are n/N (%). *Summary ignores cluster. †Adjusted for age group, sex, body-mass index group, number of tuberculosis symptoms, and HIV status. ‡Adjusted for age 
group, sex, body-mass index group, and number of tuberculosis symptoms. §Because there was no loss to follow-up in two clusters, we added one event to all clusters. 
¶Adjusted for body-mass index group and number of tuberculosis symptoms.
Table 2: Eﬀ ect of Xpert MTB/RIF on the primary and secondary outcomes
Number of deaths (%) OR*  Adjusted OR† (95% CI) p
Province 0·54
A 55/1752 (3·1%) 1 1
B 32/462 (6·9%) 2·30 1·34 (0·82–2·15)
C 76/1762 (4·3%) 1·39 0·96 (0·66–1·40)
D 30/435 (6·9%) 2·29 1·04 (0·63–1·70)
Positive index test result 0·06
No 159/4037 (3·9%) 1 1
Yes 34/374 (9·1%) 2·25 1·49 (0·99–2·24)
Sex 0·001
Male 114/1675 (6·8%) 1 1
Female 79/2739 (2·9%) 0·42 0·59 (0·43–0·82)
Age (years) 0·001
<30 32/1302 (2·5%) 1 1
30–34·9 29/704 (4·1%) 1·64 1·34 (0·80–2·29)
35–39·9 37/621 (6·0%) 2·32 2·02 (1·23–3·34)
40–49·9 42/899 (4·7%) 1·80 1·59 (0·98–2·59)
≥50 53/885 (6·0%) 2·58 2·53 (1·59–4·04)
Number of symptoms‡ <0·0001
0 2/350 (0·6%) 0·18 0·23 (0·05–0·98)
1 16/957 (1·7%) 0·52 0·59 (0·33–1·06)
2 41/1298 (3·2%) 1 1
3 62/1073 (5·8%) 1·80 1·58 (1·04–2·38)
4 72/733 (9·8%) 3·12 2·51 (1·66–3·80)
Body-mass index (kg/m²) 0·003
<18·5 41/468 (18·6%) 1·68 1·40 (0·94–2·07)
18·5–24·9 108/2020 (10·4%) 1 1
25–29·9 26/1015 (4·1%) 0·49 0·60 (0·38–0·94)
≥30 18/909 (3·7%) 0·38 0·57 (0·33–0·97)
HIV status, by self-report <0·0001
Negative 24/1276 (1·9%) 1 1
Positive, not on ART 89/1398 (6·4%) 3·15 3·32 (2·03–5·41)
Positive, on ART 26/688 (3·8%) 1·85 1·79 (0·99–3·21)
Unknown 54/1049 (5·2%) 2·78 2·41 (1·47–3·98)
ART=antiretroviral therapy. *Adjusted for province. †Adjusted for all variables in table. ‡Number of symptoms from: 
current cough, night sweats, fever, and weight loss.
Table 3: Risk factor analysis for mortality by 6 months from enrolment
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Xpert versus microscopy, perhaps because of high HIV 
prevalence in our population.3 This ﬁ nding suggests an 
important advantage of Xpert MTB/RIF testing for the 
health system, because increased detection rates will 
facilitate rapid treatment of microbiologically conﬁ rmed 
tuberculosis by nurses, with the potential to reduce 
transmission. An increase of this magnitude has the 
potential to result in cost savings both for patients and 
for tuberculosis programmes, and we are currently 
undertaking economic analyses to investigate this.
However, this increase in detection rates did not 
translate into an increased number of people receiving 
tuberculosis treatment by 6 months, suggesting that 
Xpert MTB/RIF replaced, rather than supplemented, 
empirical treatment (ie, treatment without microbiological 
conﬁ rmation). Given the pragmatic trial design, 
mycobacterial cultures were only performed if requested 
as routine by clinic staﬀ , and thus we cannot report what 
proportion of people with microbiologically conﬁ rmed 
tuberculosis started treatment in either group, nor what 
proportion of people without microbiologically conﬁ rmed 
tuberculosis received unnecessary empirical treatment.
It might be argued that the location of laboratory 
services in South Africa, usually separate from clinics, 
limits the potential beneﬁ ts of Xpert MTB/RIF. Co-
location of clinics and laboratory services could allow 
for in-session results, potentially reducing initial loss to 
follow-up and time to treatment. However, our results 
are consistent with those of the TB-NEAT trial,10 in 
which people being investigated for tuberculosis in 
primary care clinics in four African countries were 
individually randomised to on-site Xpert MTB/RIF or 
sputum microscopy, both providing same-day results.10 
In TB-NEAT, although the proportion of participants 
receiving same-day diagnosis and same-day treatment 
initiation was higher with Xpert MTB/RIF than with 
microscopy, the proportion of patients who had started 
tuberculosis treatment by 56 days was similar (43% vs 
42%), and there was no diﬀ erence in morbidity or 
mortality. The very high proportion of patients starting 
empirical treatment was probably attributable to same-
day chest radiography, provided for all patients. In our 
trial, chest radiography was at the discretion of clinic 
staﬀ  for investigation of HIV-positive people with 
negative test results, and often required travel to 
another clinic, as is common in resource-limited 
settings.
Our study enrolled people being investigated for 
tuberculosis in typical primary care clinics. However, a 
limitation of this approach is that, with a 7% prevalence 
of rifampicin resistance in tuberculosis cases in South 
Africa,13 we had too few rifampicin-resistant results to 
assess the eﬀ ect of Xpert MTB/RIF on outcomes for this 
type of tuberculosis.
The replacement of sputum microscopy with Xpert 
MTB/RIF might have a greater eﬀ ect on case detection 
and time to appropriate drug treatment, and thus 
potentially on transmission of drug-resistant tuber-
culosis.2 Further research is needed to guide policy on 
tuberculosis diagnostics in settings with high prevalence 
of drug-resistant tuberculosis.
Given that our trial was embedded within the national 
roll-out of Xpert MTB/RIF, we believe that our results 
reﬂ ect programmatic performance of the test in the 
South African health system, and are likely to be 
generalisable to settings with a similar health system to 
that in South Africa and that also have high tuberculosis 
and HIV prevalence. Our trial was pragmatic and did not 
attempt to inﬂ uence adherence to diagnostic algorithms, 
nor provide a diagnostic gold standard; this approach led 
to a further limitation in that we do not know the true 
prevalence of tuberculosis (pulmonary or extra-
pulmonary) in our participants. Our regular retention 
calls to participants were designed to maintain contact 
and were not intended to inﬂ uence clinical care. 
However, these activities could have inﬂ uenced study 
outcomes, particularly initial loss to follow-up and time 
to treatment, but since they were identical in both study 
groups they are unlikely to have had an eﬀ ect on between-
group comparisons. Imbalance of some individual-level 
factors (BMI and number of symptoms reported) at 
baseline is not uncommon in cluster-randomised trials 
with a relatively small number of clusters. In our study, 
the observed baseline imbalance suggested that patients 
selected by clinic staﬀ  to have sputum sent for 
tuberculosis testing were slightly healthier in the Xpert 
group. A possible explanation is that staﬀ  in clinics 
assigned to the Xpert group had recently been trained on 
the Xpert diagnostic algorithm by National Department 
of Health staﬀ , as part of the process of Xpert roll-out. 
This may have resulted in clinic staﬀ  initiating 
tuberculosis testing among a wider range of patients, 
including healthier patients, than happened in the 
microscopy group.
In conclusion, implementation of Xpert MTB/RIF in 
South Africa appears unlikely to improve control of 
drug-sensitive tuberculosis without improvements to 
the health system, in particular changes to reduce initial 
loss to follow-up and time to treatment initiation. We 
noted that unknown HIV status, or positive status but 
no antiretroviral therapy, were important determinants 
of mortality, which supports the policy that all people 
being investigated for tuberculosis should know their 
HIV status, and suggests the need to improve linkage 
between investigation for tuberculosis and HIV care. 
Our evaluation of Xpert MTB/RIF, conducted under 
programmatic conditions, has highlighted the 
importance of addressing health system weaknesses in 
order to maximise the eﬀ ect of new diagnostics. WHO 
recommendations should be updated to reﬂ ect the 
impact of implementing Xpert MTB/RIF under 
programmatic conditions on patient-relevant outcomes, 
and consider the broader context of the health system in 
which tests are used.
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